Cortexin vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Cortexin | Cagrilintide |
|---|---|---|
| Mechanism | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |